Yonhap Infomax NewsFeb 4
Eli Lilly posted a Q4 earnings beat as demand for its obesity drugs Zepbound and Mounjaro soared, driving revenue up 43% and sending shares up 9% in pre-market trading.
#YonhapInfomax #EliLilly #ObesityDrugs #Q4Earnings #RevenueGrowth #SharePriceSurge #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=103893
Eli Lilly Delivers Q4 Earnings Surprise on Obesity Drug Demand—Shares Surge 9%

Eli Lilly posted a Q4 earnings beat as demand for its obesity drugs Zepbound and Mounjaro soared, driving revenue up 43% and sending shares up 9% in pre-market trading.

Yonhap Infomax
Yonhap Infomax NewsJan 16
The JP Morgan Healthcare Conference spotlighted AI-biotech convergence, fierce obesity drug competition, South Korean biosimilar firms' new drug push, and Hanmi Pharmaceutical's share plunge, underscoring global shifts in pharma innovation and market dynamics.
#YonhapInfomax #JPmorganHealthcare #ArtificialIntelligence #ObesityDrugs #HanmiPharmaceutical #BiosimilarDevelopment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100312
JP Morgan Healthcare Conference Highlights—AI Integration and Intensifying New Drug Race

The JP Morgan Healthcare Conference spotlighted AI-biotech convergence, fierce obesity drug competition, South Korean biosimilar firms' new drug push, and Hanmi Pharmaceutical's share plunge, underscoring global shifts in pharma innovation and market dynamics.

Yonhap Infomax
Yonhap Infomax NewsApr 2, 2025
Hims & Hers Health adds popular obesity drugs to platform, including Zepbound and Mounjaro, driving 5% stock increase amid expanding weight loss market
#YonhapInfomax #HimsAndHersHealth #ObesityDrugs #Zepbound #Mounjaro #WeightLossTreatments #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=56748
Hims & Hers Health Adds Obesity Drugs to Platform, Stock Rises 5%

Hims & Hers Health adds popular obesity drugs to platform, including Zepbound and Mounjaro, driving 5% stock increase amid expanding weight loss market

Yonhap Infomax
Show threadTünde Nagy-BántóMay 23, 2024

"Corporate affairs professionals say #food companies are overwhelmed by the level of public concern about #UPF and are scrambling to find an effective way to counter it."
"Two-thirds of Europeans now believe that #UltraProcessedFood are unhealthy and will cause #health problems in later life (...) and do not trust that the authorities are regulating them well enough."

#FoodIndustry #diet #JunkFood #HealthyDiet #PublicHealth #policy #obesity #ObesityDrugs #BigPharma #ResearchIntegrity #MustRead

Tünde Nagy-BántóMay 23, 2024

'Deny, denounce, delay’: the battle over the risk of #UltraProcessedFood

Despite a growing body of evidence, #BigFood is trying to dampen fears about the #health effects of industrially formulated substances using the tools and tricks of the #TobaccoIndustry (register to read).

https://on.ft.com/3yxMHkr

#FoodIndustry #UPF #Nova #CarlosMonteiro #diet #JunkFood #food #HealthyDiet #PublicHealth #policy #ResearchIntegrity #obesity #ObesityDrugs #BigPharma #BigTobacco #FinancialTimes #FT #MustRead

‘Deny, denounce, delay’: the battle over the risk of ultra-processed foods

Despite a growing body of evidence, Big Food is trying to dampen fears about the health effects of industrially formulated substances